Comparative Pharmacology
Head-to-head clinical analysis: NUFYMCO versus SELSUN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUFYMCO versus SELSUN.
NUFYMCO vs SELSUN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NUFYMCO is a lipid-regulating agent. Its mechanism involves activation of peroxisome proliferator-activated receptor alpha (PPARα), leading to increased lipolysis and elimination of triglyceride-rich particles from plasma, and reduced VLDL production.
Selenium sulfide is an antifungal agent that inhibits the growth of Malassezia species by reducing selenium to elemental selenium, which is toxic to the fungus. It also reduces sebum production via unknown mechanisms.
NUFYMCO is a proprietary combination product; standard adult dosing is one capsule (25 mg bempedoic acid/20 mg ezetimibe) orally once daily.
Apply 5-10 mL of 2.5% selenium sulfide lotion to affected areas of scalp, lather with water, leave on for 2-3 minutes, then rinse thoroughly. Use twice weekly for 2 weeks, then once weekly for maintenance.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults, allowing twice-daily dosing; prolonged to 24-36 hours in moderate renal impairment
Not well defined due to minimal systemic absorption; topical application yields negligible plasma levels.
Renal (60-70% as unchanged drug), biliary/fecal (20-30% as metabolites and unchanged drug)
Selenium sulfide is minimally absorbed; absorbed portions are excreted renally (approx. 80-90%) and fecally (10-20%).
Category C
Category C
Antifungal
Antifungal/Antiseborrheic